HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Steinbach, J. J. Articles by Goldman, J. K. Search for Related Content PubMed PubMed Citation Articles by Steinbach, J. J. Articles by Goldman, J. K.

Simultaneous Treatment of Toxic Diffuse Goiter with I-131 and Antithyroid Drugs: A Prospective Study

Veterans Administration Medical Center, and State University of New York at Buffalo, Buffalo, New York

Correspondence: For reprints contact: Jehuda J. Steinbach, Nuclear Medicine Service, Veterans Administration Medical Center, 3495 Bailey Ave., Buffalo, NY 14215.

ABSTRACT

We report a prospective study to evaluate the effect of antithyroid drugs containing the sulfhydryl radical on the outcome of I-131 (RAI) therapy.

Twenty-four male patients with toxic diffuse goiter were assigned randomly into two treatment groups: Group A received RAI treatment while on antithyroid drugs after attainment of euthyroidism; Group B received no antithyroid drugs before, or when, RAI was given. Patients in each group received a dose of RAI calculated to deliver approximately 5000 rads per treatment.

The incidence of hypothyroidism at 12 mo was 8% for Group A and 36% for Group B (p <0.01). During 12–102 mo of follow-up, no additional hypothyroidism was encountered in Group A. Two patients with significantly elevated TSH levels were found in Group B, one at 20 mo and one at 75 mo after RAI. The mean time to cure was 15.2 ± 9.1 mo for Group A and 19.7 ± 8.2 mo for Group B (NS: p >0.45).

The improved therapeutic outcome of patients in Group A suggests that further validation of the method in a larger patient population, including females, is warranted.

This article has been cited by other articles:

				O. Sabri, M. Zimny, G. Schulz, M. Schreckenberger, P. Reinartz, K. Willmes, and U. Buell Success Rate of Radioiodine Therapy in Graves' Disease: The Influence of Thyrostatic Medication J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1229 - 1233. [Abstract] [Full Text]